| Vol. 12.10 – 16 March, 2023 |
| |
|
|
| Researchers studied the pathogenesis of vascular remodeling in fibrotic lungs and its contribution to the progression of fibrosis. They used an experimental model of lung fibrosis associated with pulmonary hypertension by transient overexpression of active TGF-β1. [American Journal Of Respiratory And Critical Care Medicine] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To decrease the bystander edits, scientists used a specific adenosine base editing (ABE), NG-ABEmax, which was delivered as mRNA. The NG-ABEmax RNA approach was validated in patient-derived rectal organoids and bronchial epithelial cells showing sufficient gene correction to recover the CFTR function. [Molecular Therapy] |
|
|
|
| Researchers characterized the functional consequences of seven KCNA5 variants found in a cohort of pulmonary arterial hypertension patients. [American Journal Of Respiratory Cell And Molecular Biology] |
|
|
|
| Investigators explored the role and the underlying molecular mechanisms of m6A methylation of Nrf2 mRNA in PM2.5-induced pulmonary fibrosis. [Ecotoxicology And Environmental Safety] |
|
|
|
| In vitro respiratory syncytial virus (RSV) infection models using A549 and 16HBE cell lines were established, and the effects of andrographolide on RSV were analyzed via RSV N gene load and proinflammatory cytokine levels. [Molecular Biology Reports] |
| |
|
|
| To build a preclinical platform that covered the broad disease spectrum of human lung cancer, the authors obtained lung cancer specimens from multiple sources, including sputum and circulating tumor cells, and generated a living biobank consisting of 43 lines of patient-derived lung cancer organoids. [Cell Reports] |
|
|
|
| Scientists revealed the subtype specificity of BCL-2 expression and shed light on the mechanism of venetoclax resistance in SCLC. [British Journal Of Cancer] |
|
|
|
| Investigators established in vivo animal models of gefitinib-induced drug-resistant lung cancer containing EGFRL858R and EGFRL858R*Tp53+/− mice to explore the molecular mechanisms of drug resistance by studying the genomic integrity and global gene expression. [Cell Death Discovery] |
|
|
|
| Researchers studied whether these underlying mechanisms affect the prognostic role of programmed cell death ligand 1 (PD-L1). They enrolled patients with EGFR mutant advanced-stage NSCLC who received first-line EGFR-TKI between January 2017 and June 2019, and the treatment efficacy was assessed. [Scientific Reports] |
|
|
|
|
| The authors outline the potential and possibilities of using CRISPR/Cas9-based gene-editing technology in cystic fibrosis modeling. [Advances In Medical Sciences] |
|
|
|
|
| The primary objectives of the THIO-101 trial were to evaluate the safety and tolerability, as well as preliminary clinical efficacy of THIO, a first-in-class cancer telomere targeting agent, in patients with advanced NSCLC. [MAIA Biotechnology, Inc.] |
|
|
|
|
| March 31, 2023 Amsterdam, The Netherlands |
|
|
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| University of California, San Francisco – San Francisco, California, United States |
|
|
|
| University of Virginia – Charlottesville, Virginia, United States |
|
|
|
| STEMCELL Technologies – Vancouver, British Columbia, Canada |
|
|
|
|